PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33559413-1	2021	BACKGROUND: The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown.	Platinum	66-74	BRCA1 DNA repair associated	Homo sapiens	37-41	
33559413-4	2021	METHODS: BRCA wild-type patients who received two previous courses of platinum-containing therapy, achieved complete or partial response to last treatment, and the treatment-free interval is >6 months after the penultimate platinum-based chemotherapy offered olaparib maintenance with pembrolizumab and bevacizumab.	Platinum	70-78	BRCA1 DNA repair associated	Homo sapiens	9-13	
33559413-4	2021	METHODS: BRCA wild-type patients who received two previous courses of platinum-containing therapy, achieved complete or partial response to last treatment, and the treatment-free interval is >6 months after the penultimate platinum-based chemotherapy offered olaparib maintenance with pembrolizumab and bevacizumab.	Platinum	223-231	BRCA1 DNA repair associated	Homo sapiens	9-13